Corixa [CRXA] - cancer vaccines Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Corixa [CRXA] - cancer vaccines

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: SemiBull who wrote (157)	8/12/2002 9:10:31 PM
From: SemiBull	Read Replies (1) of 222

Corixa Announces $45 M Private Placement Financing SEATTLE -(Dow Jones)- Corixa Corp (NasdaqNM:CRXA - News). expects to receive gross proceeds of about $45 million from a private placement to institutional and other accredited investors. In a press release Monday, the company said it plans to use the financing for research and development, working capital and general corporate purposes. The immunotherapeutic products developer agreed to sell about 7.3 million shares for $6.13 each. For an additional 12.5 cents per underlying share, the investors will purchase about 1.2 million five-year warrants to acquire common shares for $6.13 each. The deal, subject to customary closing conditions, is expected to close Aug. 14. InterWest Partners led the financing, which includes investments from BankAmerica Ventures, Frazier Healthcare (AMEX:HCT - News) Ventures, Hambrecht & Quist Capital Management LLC, KBL Healthcare Ventures, Oxford Bioscience Partners and Sutter Hill Ventures. Pacific Growth Equities Inc. was the placement agent. Nasdaq shares of Corixa closed Friday, down 3 cents to $6.12. Company Web site: corixa.com -Eamon Beltran; Dow Jones Newswires; 201-938-5400

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next